[Epidemiology, clinical features and betaserc therapy of vertigo in initial and reversible cerebrovascular pathology].
The study comprised two sections: epidemiologic and clinical. The aim of the epidemiologic investigation was to determine prevalence of vertigo, including its mild cases, in patients with initial and reversible forms of cerebrovascular pathology. While screening an open population, 726 men and women aged 35-60 years have been examined using uniform program. Vertigo was detected in 30%, frequent and long-lasting one in 14.6% cases (8.1% men and 21.9% women, p < 0.001). A clinical section included a profound examination of 40 patients. Along with duplex scanning of major brain arteries, neurologic and otoneurologic examination of the patients, aucoustic stem evoked potentials have been registered. Marked dysfunctions of autonomic nervous system and changes in functioning of different vestibular analyzer regions were revealed. High efficacy of betaserk used during 2 months in dosage 16 mg three times a day was demonstrated by improvement of the patient's state in 97% cases.
Gornostaeva
G V
GV
Varakin
Iu Ia
IuIa
Prokopovich
M E
ME
Alekseeva
N S
NS
Fedin
P A
PA
Chechetkin
A O
AO
D000328:Adult; D000368:Aged; D001621:Betahistine / Q000627:therapeutic use*; D001921:Brain / Q000098:blood supply*; D002560:Cerebrovascular Circulation / Q000502:physiology; D005072:Evoked Potentials, Auditory / Q000502:physiology; D005260:Female; D017442:Histamine Agonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000379:methods; D008875:Middle Aged; D012720:Severity of Illness Index; D014717:Vertigo / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology
D017442:Histamine Agonists; D001621:Betahistine